Saireito (114) Increases IC50 and Changes T-Cell Phenotype When Used in Combination with Prednisolone Therapy in Human Peripheral Blood Mononuclear Cells

Figure 5

Dot plot and cell positive rate of Tfh cells in the PBMCs after PSL and 114 treatments. (a) Dot plot upon gating CXCR5⁺PD-1⁺ cells (Tfh cells) in the subcellular fractions of CD4⁺ T cells of PBMCs stimulated by ConA after PSL and 114 treatments. After gating in a PerCP-Cy5-5A-FSC-A dot plot, FITC-A in the subcellular fractions was gated on the vertical axis, and Alexa Fluor 647-A was gated on the horizontal axis. The first quadrant of the dot plot was Tfh cells, and the ratio was calculated by the number of CXCR5 and PD-1-stained cells / the number of CD4-stained cells  100. (b) Ratio of Tfh cells in PBMCs stimulated by ConA after PSL and 114 treatments. Each treatment was compared to its respective blank using Dunnett’s multiple comparisons test (; ). The PSL monotherapy group and the PSL + 114 combination therapy groups were compared using the Tukey–Kramer multiple comparison test (mean + SD, n = 6). ConA: concanavalin A, PBMCs: peripheral blood mononuclear cells, PSL: prednisolone, and 114: saireito.

(a)

(b)